The ciliary smooth muscle electrotransfer: Basic principles and potential for sustained intraocular production of therapeutic proteins

Journal of Gene Medicine

Volumn 12, Issue 11, 2010, Pages 904-919

  Touchard, Elodie ^a,b,c   Kowalczuk, Laura ^a,b   Bloquel, Carole ^a,b   Naud, Marie Christine ^a,b   Bigey, Pascal ^b,d,e,f   Behar Cohen, Francine ^a,b,g  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^d INSERM   (France)

^e CNRS   (France)

^f PSL RESEARCH UNIVERSITY   (France)

^g HÔTEL DIEU   (France)

Author keywords

Electrotransfer; Eye; Nonviral gene therapy; Plasmid DNA; Protein delivery; Smooth muscle

Indexed keywords

BETA GALACTOSIDASE; LUCIFERASE; PLASMID DNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHILD; CILIARY MUSCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ELECTRODE; ELECTROPORATION; EXPERIMENTAL RABBIT; FEMALE; GENE EXPRESSION; GROUPS BY AGE; HUMAN; MALE; NEEDLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMID; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN SECRETION; RAT; REPORTER GENE; SCHOOL CHILD; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AQUEOUS HUMOR; BETA-GALACTOSIDASE; CHILD; CHILD, PRESCHOOL; CILIARY BODY; ELECTROPORATION; EYE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LUCIFERASES; MALE; MIDDLE AGED; MODELS, ANIMAL; MUSCLE, SMOOTH; PLASMIDS; RABBITS; RATS; RATS, INBRED LEW;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 78649502295     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1517     Document Type: Article

References (71)

1. Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26: 1197-1216.
2. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008; 13: 135-143.
3. Bourges JL, Touchard E, Kowalczuk L, et al. [Drug delivery systems for intraocular applications]. J Fr Ophtalmol 2007; 30: 1070-1088.
4. Booth BA, Vidal Denham L, Bouhanik S, et al. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 2007; 24: 581-602
5. Chung DC, Lee V, Maguire AM. Recent advances in ocular gene therapy. Curr Opin Ophthalmol 2009; 20: 377-381.
6. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009; 15: 23-31.
7. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. Gene Ther 2006; 13: 1191-1197.
8. Conley SM, Cai X, Naash MI. Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther 2008; 10: 456-463.
9. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
10. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008; 105: 15112-15117.
11. Andrieu-Soler C, Bejjani RA, de Bizemont T, et al. Ocular gene therapy: a review of nonviral strategies. Mol Vis 2006; 12: 1334-1347.
12. Bloquel C, Bourges JL, Touchard E, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006; 58: 1224-1242.
13. Naik R, Mukhopadhyay A, Ganguli M Gene delivery to the retina: focus on non-viral approaches. Drug Discov Today 2009; 14: 306-315.
14. Ledwith BJ, Manam S, Troilo PJ, et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000; 43: 258-272.
15. Wolff JA, Ludtke JJ, Acsadi G, et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1: 363-369.
16. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11: 711-721.
17. Escoffre JM, Portet T, Wasungu L, et al. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol Biotechnol 2009; 41: 286-295.
18. Rols MP. Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods Mol Biol 2008; 423: 19-33.
19. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007; 7: 67-77.
20. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
21. Mir LM, Bureau MF, Rangara R, et al. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. CR Acad Sci III 1998; 321: 893-899.
22. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999; 96: 4262-4267.
23. Mir LM, Moller PH, Andre F, et al. Electric pulse-mediated gene delivery to various animal tissues. Adv Genet 2005; 54: 83-114.
24. Bejjani RA, Andrieu C, Bloquel C, et al. Electrically assisted ocular gene therapy. Surv Ophthalmol 2007; 52: 196-208.
25. Bettan M, Emmanuel F, Darteil R, et al. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2000; 2: 204-210.
26. Muramatsu T, Arakawa S, Fukazawa K, et al. In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Int J Mol Med 2001; 7: 37-42.
27. Trollet C, Scherman D, Bigey P. Delivery of DNA into muscle for treating systemic diseases: advantages and challenges. Methods Mol Biol 2008; 423: 199-214.
28. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009; 17: 585-592.
29. Hojman P. Basic principles and clinical advancements of muscle electrotransfer. Curr Gene Ther 2010; 10: 128-138.
30. Bloquel C, Bejjani R, Bigey P, et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. FASEB J 2006; 20: 389-391.
31. Kowalczuk L, Touchard E, Camelo S, et al. Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Invest Ophthalmol Vis Sci 2009; 50: 1761-1768.
32. Touchard E, Bloquel C, Bigey P, et al. Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis. Gene Ther 2009; 16: 862-873.
33. Bloquel C, Denys A, Boissier MC, et al. Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice. J Gene Med 2007; 9: 986-993.
34. Khoury M, Bigey P, Louis-Plence P, et al. A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. J Gene Med 2006; 8: 1027-1036.
35. Corovic S, Pavlin M, Miklavcic D. Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations. Biomed Eng Online 2007; 6: 37.
36. Oshima Y, Sakamoto T, Yamanaka I, et al. Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther 1998; 5: 1347-1354.
37. Oshima Y, Sakamoto T, Hisatomi T, et al. Targeted gene transfer to corneal stroma in vivo by electric pulses. Exp Eye Res 2002; 74: 191-198.
38. Sakamoto T, Oshima Y, Nakagawa K, et al. Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness. Hum Gene Ther 1999; 10: 2551-2557.
39. Blair-Parks K, Weston BC, Dean DA. High-level gene transfer to the cornea using electroporation. J Gene Med 2002; 4: 92-100.
40. Zhou R, Dean DA Gene transfer of interleukin 10 to the murine cornea using electroporation. Exp Biol Med (Maywood) 2007; 232: 362-369.
41. Dezawa M, Takano M, Negishi H, et al. Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron 2002; 33: 1-6.
42. Mo X, Yokoyama A, Oshitari T, et al. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest Ophthalmol Vis Sci 2002; 43: 2401-2405.
43. Kachi S, Oshima Y, Esumi N, et al. Nonviral ocular gene transfer. Gene Ther 2005; 12: 843-851.
44. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA 2004; 101: 16-22.
45. Chalberg TW, Genise HL, Vollrath D, et al. phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci 2005; 46: 2140-2146.
46. Johnson CJ, Berglin L, Chrenek MA, et al. Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol Vis 2008; 14: 2211-2226.
47. Kachi S, Esumi N, Zack DJ, et al. Sustained expression after nonviral ocular gene transfer using mammalian promoters. Gene Ther 2006; 13: 798-804.
48. Ishikawa H, Takano M, Matsumoto N, et al. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 2005; 12: 289-298.
49. Zampaglione I, Arcuri M, Cappelletti M, et al. In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters. J Gene Med 2005; 7: 1475-1481.
50. Cukjati D, Batiuskaite D, Andre F, et al. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 2007; 70: 501-507.
51. Mathiesen I Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-514.
52. Gollins H, McMahon J, Wells KE, et al. High-efficiency plasmid gene transfer into dystrophic muscle. Gene Ther 2003; 10: 504-512.
53. Molnar MJ, Gilbert R, Lu Y, et al. Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol Ther 2004; 10: 447-455.
54. Rubenstrunk A, Mahfoudi A, Scherman D. Delivery of electric pulses for DNA electrotransfer to mouse muscle does not induce the expression of stress related genes. Cell Biol Toxicol 2004; 20: 25-31.
55. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
56. Schertzer JD, Plant DR, Lynch GS. Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function. Mol Ther 2006; 13: 795-803.
57. Wang XD, Tang JG, Xie XL, et al. A comprehensive study of optimal conditions for naked plasmid DNA transfer into skeletal muscle by electroporation. J Gene Med 2005; 7: 1235-1245.
58. Durieux AC, Bonnefoy R, Busso T, et al. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J Gene Med 2004; 6: 809-816.
59. Yan CN, Li F, Patterson C, et al. High-voltage and high-salt buffer facilitates electroporation of human aortic smooth-muscle cells. Biotechniques 1998; 24: 590-592.
60. Lee MJ, Cho SS, Jang HS, et al. Optimal salt concentration of vehicle for plasmid DNA enhances gene transfer mediated by electroporation. Exp Mol Med 2002; 34: 265-272.
61. Guo ZS, Li Q, Bartlett DL, et al. Gene transfer: the challenge of regulated gene expression. Trends Mol Med 2008; 14: 410-418.
62. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859.
63. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-2182.
64. McMahon JM, Signori E, Wells KE, et al. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase-increased expression with reduced muscle damage. Gene Ther 2001; 8: 1264-1270.
65. McMahon JM, Wells KE, Bamfo JE, et al. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther 1998; 5: 1283-1290.
66. Liu F, Huang LA. syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther 2002; 5: 323-328.
67. Vicat JM, Boisseau S, Jourdes P, et al. Muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression. Hum Gene Ther 2000; 11: 909-916.
68. Sersa G, Cemazar M, Snoj M. Electrochemotherapy of tumours. Curr Oncol 2009; 16: 34-35.
69. Mir LM. Application of electroporation gene therapy: past, current, and future. Methods Mol Biol 2008; 423: 3-17.
70. Rabussay D Applicator and electrode design for in vivo DNA delivery by electroporation. Methods Mol Biol 2008; 423: 35-59.
71. Mir LM. Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 2009; 43: 167-176.